Onconova Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule product candidates to treat cancer. Its product candidates include Rigosertib IV, which is in Phase III clinical trial for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trial for patients with higher-risk MDS; and Rigosertib oral, which is in Phase II clinical trial for patients with lower risk MDS.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone267-759-3680
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.23 million
Profitability
Miscellaneous
Employees25
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable
Onconova Therapeutics (NASDAQ:ONTX) Frequently Asked Questions
What is Onconova Therapeutics' stock symbol?
Onconova Therapeutics trades on the NASDAQ under the ticker symbol "ONTX."
When did Onconova Therapeutics' stock split? How did Onconova Therapeutics' stock split work?
Onconova Therapeutics's stock reverse split before market open on Wednesday, September 26th 2018. The 1-15 reverse split was announced on Tuesday, September 25th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 25th 2018. An investor that had 100 shares of Onconova Therapeutics stock prior to the reverse split would have 7 shares after the split.
How were Onconova Therapeutics' earnings last quarter?
Onconova Therapeutics Inc (NASDAQ:ONTX) announced its quarterly earnings results on Wednesday, August, 14th. The biopharmaceutical company reported ($0.60) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.98) by $0.38. The biopharmaceutical company had revenue of $2.02 million for the quarter, compared to analysts' expectations of $0.25 million. Onconova Therapeutics had a negative net margin of 976.64% and a negative return on equity of 872.01%. View Onconova Therapeutics' Earnings History.
When is Onconova Therapeutics' next earnings date?
What price target have analysts set for ONTX?
3 Wall Street analysts have issued 1-year price targets for Onconova Therapeutics' shares. Their forecasts range from $8.00 to $25.00. On average, they expect Onconova Therapeutics' stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 1,245.3% from the stock's current price. View Analyst Price Targets for Onconova Therapeutics.
What is the consensus analysts' recommendation for Onconova Therapeutics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Onconova Therapeutics.
What are Wall Street analysts saying about Onconova Therapeutics stock?
Here are some recent quotes from research analysts about Onconova Therapeutics stock:
- 1. According to Zacks Investment Research, "Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecule drug candidates to treat cancer. The Company's products under different phases of development include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. " (10/19/2019)
- 2. Maxim Group analysts commented, "Onconova announced that it has entered into a license agreement with HanX Biopharmaceuticals, Inc. (HanX, private) in China to develop and commercialize the company’s lead asset, rigosertib, which is currently in an ongoing pivotal P3 study (INSPIRE) for the treatment of higher-risk MDS (HR-MDS). This expands the collaboration with HanX, which already includes Onconova’s ON 1233000 (CDK 4/6 + ARK5 inhibitor)." (5/14/2019)
- 3. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $25 price target. Our clinical NPV model, driven by rigostertib in MDS, allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway. Onconova Therapeutics, Inc." (2/8/2019)
Has Onconova Therapeutics been receiving favorable news coverage?
Media headlines about ONTX stock have been trending extremely negative recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Onconova Therapeutics earned a daily sentiment score of -4.6 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for Onconova Therapeutics.
Are investors shorting Onconova Therapeutics?
Onconova Therapeutics saw a decrease in short interest during the month of September. As of September 15th, there was short interest totalling 320,300 shares, a decrease of 12.2% from the August 15th total of 364,900 shares. Based on an average trading volume of 150,700 shares, the short-interest ratio is presently 2.1 days. Currently, 5.6% of the company's stock are short sold. View Onconova Therapeutics' Current Options Chain.
Who are some of Onconova Therapeutics' key competitors?
Some companies that are related to Onconova Therapeutics include Aerpio Pharmaceuticals (ARPO), AEterna Zentaris (AEZS), Cassava Sciences (SAVA), Seelos Therapeutics (SEEL), Aytu Bioscience (AYTU), RegeneRx Biopharmaceuticals (RGRX), BIOLINERX LTD/S (BLRX), Kazia Therapeutics (KZIA), Earth Science Tech (ETST), Evoke Pharma (EVOK), AzurRx BioPharma (AZRX), KemPharm (KMPH), Guardion Health Sciences (GHSI), Soligenix (SNGX) and Amarillo Biosciences (AMAR).
What other stocks do shareholders of Onconova Therapeutics own?
Who are Onconova Therapeutics' key executives?
Onconova Therapeutics' management team includes the folowing people:
- Dr. Steven M. Fruchtman, CEO, Pres & Director (Age 68)
- Dr. E. Premkumar Reddy, Founder, Lead Scientific Advisor & Director (Age 75)
- Dr. Manoj Maniar, Sr. VP of Product Devel. (Age 56)
- Dr. Ramesh Kumar, Advisor (Age 63)
- Mr. Mark Patrick Guerin, Chief Financial Officer (Age 50)
How do I buy shares of Onconova Therapeutics?
Shares of ONTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Onconova Therapeutics' stock price today?
One share of ONTX stock can currently be purchased for approximately $1.12.
How big of a company is Onconova Therapeutics?
Onconova Therapeutics has a market capitalization of $6.69 million and generates $1.23 million in revenue each year. The biopharmaceutical company earns $-20,570,000.00 in net income (profit) each year or ($4.99) on an earnings per share basis. Onconova Therapeutics employs 25 workers across the globe.View Additional Information About Onconova Therapeutics.
What is Onconova Therapeutics' official website?
How can I contact Onconova Therapeutics?
Onconova Therapeutics' mailing address is 375 PHEASANT RUN, NEWTOWN PA, 18940. The biopharmaceutical company can be reached via phone at 267-759-3680 or via email at [email protected]
MarketBeat Community Rating for Onconova Therapeutics (NASDAQ ONTX)
MarketBeat's community ratings are surveys of what our community members think about Onconova Therapeutics and other stocks. Vote "Outperform" if you believe ONTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
